Extrafine beclometasone/formoterol is non-inferior to budesonide/formoterol as maintenance and reliever therapy (MART) for adult asthma patients and reduces the total carbon footprint of all inhaler-related greenhouse gas (GHG) emissions. - Amsterdam 2025

Environmental sustainability in the management of airway diseases: novel alpha-1 antitrypsin data and innovations in drug delivery

Chair(s): Miriam Barrecheguren Fernandez, Kristian Brat

Session type: Poster session

Extrafine beclometasone/formoterol is non-inferior to budesonide/formoterol as maintenance and reliever therapy (MART) for adult asthma patients and reduces the total carbon footprint of all inhaler-related greenhouse gas (GHG) emissions.

Christine Jenkins

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

The grass is greener on the other side: the environmental impact of using alternative inhalers for obstructive airways disease in a UK sleep and ventilation clinic

Orestis Aniftos

Poster

Abstract

Comparison between deposition of two dry powder aerosol drugs within the airways of patients with COPD.

Janos Tamas Varga

Poster

Abstract

Comparative in-vitro performance evaluation of two fluticasone furoate/ vilanterol/umeclidinium (100/25/62.5 mcg) multi-dose dry powder inhalers

Meena Lopez

Poster

Abstract

Evaluation of Different Spacers Available in Chile for Salbutamol Delivery in Children and Adults

Homero Puppo

Poster

Abstract

In-line aerosol nebulization with high-flow nasal cannula: a safety and feasibility study

Matthew Dartt

Poster

Abstract

Christine Jenkins

Poster

Abstract

Developing low carbon MDIs to support future patient availability: effects of HFA-152a on lung mucociliary clearance

Laura Clow

Poster

Abstract

Developing low carbon salbutamol MDI: assessment of pharmacodynamic bioequivalence of salbutamol with propellant HFA-152a via methacholine challenge

Dave Singh

Poster

Abstract

Hospital inhaler waste what are we throwing away?

Anna Murphy

Poster

Abstract

Efficacy and sustainability of endoscopic lung volume reduction in patients with emphysema due to alpha-1-antitrypsin deficiency

Sandra Tielke

Poster

Abstract

Drug delivery from a Metered Dose Inhaler (MDI) / Spacer delivering triple therapy and self reported observations from COPD patients following the introduction of a Spacer

Jason Suggett

Poster

Abstract

Optimizing COPD Management: Balancing Clinical Efficacy and Environmental Impact of Inhaled Therapies

Chung-yu Chen

Poster

Abstract

Survey to understand Indian physicians perspectives on the use of nebulized drugs in asthma and COPD exacerbations (NEBASCO)

Indranil Halder

Poster

Abstract

Lung transplant outcomes in in patients with alpha1-antitrypsin deficiency (a1ATD), retrospective study from two Italian lung Transplant centres.

Federica Meloni

Poster

Abstract

Reducing oral deposition of inhaled corticosteroids with a valved holding chamber: a quantitative study

Yvonne Burmeister

Poster

Abstract

Climate Impact of Inhalers: Patient Empowerment Drives Prescription Change

Rosemarie Vincent

Poster

Abstract

Currently used metrics overestimate the environmental effects of aerosol metered dose inhalers

Gary James Connett

Poster

Abstract

Unveiling Genetic Diversity in Alpha-1 Antitrypsin Deficiency: Case Report of Two Siblings with the Novel SERPINA1 Mutation Pi*c.236T>A

Arturo Olivares Rivera

Poster

Abstract

Augmentation Therapy in Intermediate Alpha-1 Antitrypsin Deficiency

Anna Annunziata

Poster

Abstract

Targeting Asthma in a Polluted World: A Single-Centre Study on the Relationship Between Air Pollution and Response to Asthma Biologic Therapy

Luca Nart

Poster

Abstract

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}